These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 26771938

  • 1. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.
    Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, Xu T, Xu Y, Gill IS, Quinn DI, Goldkorn A.
    Prostate; 2016 May; 76(6):597-608. PubMed ID: 26771938
    [Abstract] [Full Text] [Related]

  • 2. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
    Zeng X, Hu Z, Wang Z, Tao J, Lu T, Yang C, Lee B, Ye Z.
    Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
    [Abstract] [Full Text] [Related]

  • 3. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C, Corbin JM, Thibivilliers S, Webb ZD, Zhao YD, Koster J, Fung KM, Asch AS, Wren JD, Ruiz-Echevarría MJ.
    BMC Cancer; 2019 May 06; 19(1):423. PubMed ID: 31060542
    [Abstract] [Full Text] [Related]

  • 4. Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer.
    Waldbillig F, Nitschke K, Abdelhadi A, von Hardenberg J, Nuhn P, Nientiedt M, Weis CA, Michel MS, Erben P, Worst TS.
    Int J Mol Sci; 2020 Jun 19; 21(12):. PubMed ID: 32575490
    [Abstract] [Full Text] [Related]

  • 5. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.
    Eur Urol; 2014 Sep 19; 66(3):550-60. PubMed ID: 24836057
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings.
    Lee G, Veltri RW, Zhu G, Ali S, Epstein JI, Madabhushi A.
    Eur Urol Focus; 2017 Oct 19; 3(4-5):457-466. PubMed ID: 28753763
    [Abstract] [Full Text] [Related]

  • 10. Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.
    Sun X, Liu Z, Yang Z, Xiao L, Wang F, He Y, Su P, Wang J, Jing B.
    Diagn Pathol; 2013 Dec 18; 8():208. PubMed ID: 24350576
    [Abstract] [Full Text] [Related]

  • 11. Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.
    Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F.
    Eur Urol Focus; 2019 Nov 18; 5(6):998-1006. PubMed ID: 29609897
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
    Walz J, Chun FK, Klein EA, Reuther A, Saad F, Graefen M, Huland H, Karakiewicz PI.
    J Urol; 2009 Feb 18; 181(2):601-7; discussion 607-8. PubMed ID: 19084864
    [Abstract] [Full Text] [Related]

  • 14. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
    Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY.
    Lancet Oncol; 2014 Dec 18; 15(13):1469-1480. PubMed ID: 25456366
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
    Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G.
    Am J Surg Pathol; 2004 Jul 18; 28(7):928-34. PubMed ID: 15223964
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.